Targeted therapy with eculizumab for inherited CD59 deficiency

New England Journal of Medicine

Volumn 370, Issue 1, 2014, Pages 90-92

  Höchsmann, Britta ^a   Dohna Schwake, Christian ^b   Kyrieleis, Henriette A ^c   Pannicke, Ulrich ^d   Schrezenmeier, Hubert ^d  

^a Baden Wuerttemberg   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c Department of Cardiology Hospital Bethanien Moers   (Germany)

^d UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; DNA; ECULIZUMAB; MONOCLONAL ANTIBODY;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; AUTOSOMAL RECESSIVE DISORDER; AUTOSOMAL RECESSIVE INHERITANCE; CHILD; CHILDHOOD DISEASE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; FLOW CYTOMETRY; GENE MUTATION; HOMOZYGOSITY; HUMAN; INHERITED CD56 DEFICIENCY; LETTER; LOADING DRUG DOSE; MEDICAL HISTORY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE DRUG DOSE; ANEMIA, HEMOLYTIC; BLOOD; CASE REPORT; DRUG EFFECTS; FEMALE; HEMOGLOBINURIA; HEMOLYSIS; INFANT;

ANEMIA, HEMOLYTIC; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HEMOGLOBINURIA; HEMOLYSIS; HUMANS; INFANT;

EID: 84892179463     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1308104     Document Type: Letter

References (5)

1. Nevo Y, Ben-Zeev B, Tabib A., et al CD59 deficiency is associated with chronic hemolysis and childhood relapsing immunemediated polyneuropathy. Blood 2013;121:129-35.
2. Singhrao SK, Neal JW, Rushmere N.K., Morgan BP, Gasque P. Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis. Am J Pathol 2000;157:905-18.
3. Hillmen P, Young NS, Schubert J, et al The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006;355:1233-43.
4. Legendre CM, Licht C, Muus P., et al Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;368:2169-81.
5. Pittock SJ, Lennon VA, McKeon A, et al Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013;12:554-62.